NAPRT and ovarian cancer: A study by Piacente et al. showed that 2-hydroxynicotinic acid (2-HNA), an NAPRT inhibitor, can sensitize ovarian cancer cells to treatment with an NAMPT inhibitor, resulting in the marked cell death of OVCAR5 cells in vitro, as well as OVCAR5 in xenograft-bearing mice [68].